The selected pIGF1R/InsR antibody was chosen based on a previous publication evaluating the expression of pIGF1R/InsR in breast cancer tissue with IHC, and the specificity by treating DU145 prostate cancer cells with a IGF1R tyrosine kinase inhibitor [19]. Here, IGF1R is linked to prostate cancer.